• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640408)   Today's Articles (194)   Subscriber (50356)
For: Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy? ACTA ACUST UNITED AC 2014. [DOI: 10.2217/ijr.14.18] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Number Cited by Other Article(s)
1
Bhullar AK, Chew ZC, Ong PS, Khor CG, Mohd Amin NH. Cardiomyopathy following COVID-19 vaccination in a patient with systemic lupus erythematosus. Mod Rheumatol Case Rep 2023;7:87-91. [PMID: 36069645 PMCID: PMC9494418 DOI: 10.1093/mrcr/rxac070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 08/06/2022] [Accepted: 09/01/2022] [Indexed: 06/15/2023]
2
Chandramohan P, Jain A, Antony G, Krishnan N, Shenoy P. Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact. Rheumatol Adv Pract 2021;5:rkaa077. [PMID: 33605940 PMCID: PMC7878847 DOI: 10.1093/rap/rkaa077] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 11/25/2020] [Indexed: 12/25/2022]  Open
3
Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. RHEUMATOLOGY SCIENCE AND PRACTICE 2019. [DOI: 10.14412/1995-4484-2019-3-40] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
4
Nasonov EL, Mazurov VI, Zonova EV, Knyazeva LA, Marusenko IM, Nesmeyanova OB, Plaksina TV, Shapovalova YS, Ilivanova EP, Krechikova DG, Petrochenkova NA, Reshetko OV, Denisov LN, Gordeev IG, Davydova AF, Eremina NA, Zemerova EV, Ivanova TB, Kastanayan AA, Pokrovskaya TG, Smakotina SA, Smolyarchuk EA, Artemyeva AV, Ivanov RA, Usacheva YV, Chernyaeva EV. THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL. RHEUMATOLOGY SCIENCE AND PRACTICE 2017. [DOI: 10.14412/1995-4484-2017-351-359] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
5
Zhang J, Zhao Z, Hu X. Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis. Cell Biochem Biophys 2016;72:197-201. [PMID: 25490907 DOI: 10.1007/s12013-014-0437-z] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
6
Mota P, Reddy V, Isenberg D. Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. Expert Rev Clin Immunol 2016;13:667-676. [PMID: 27841031 DOI: 10.1080/1744666x.2017.1259068] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA